The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

New SAMHSA data shows continued declines in past-month and past-year cannabis use among 12–25 year-olds. Here’s what changed, why it matters, and how DMV policymakers may apply it.

A closed-door, two-day SAMHSA consultation in Washington, DC convened federal reps, researchers, regulators, and entrepreneurs to tackle psychedelic data gaps—no drug developers invited.

A five-year trend lens and siloed fentanyl questions in SAMHSA’s 2025 NSDUH blur key opioid metrics, complicating treatment planning and policy for the DMV.

The 2025 NSDUH shows estimated past-month marijuana use among teens aged 12–17 dropped to 5.0% — a multi-decade low — while young adults aged 18–25 trended downward or stable. Here is what the federal data actually says, what it means for the DMV, and why compliant adult-use markets may be part of the reason.